

1 **Symptoms persisting after hospitalization for COVID-19: 12 months**
2 interim results of the COFLOW study

3

4 L.M. Bek^{1*}, J.C. Berentschot^{2*}, M.H. Heijnenbrok-Kal^{1,3}, S. Huijts², M.E. van Genderen⁴, J.H. Vlake⁴, J.
5 van Bommel⁴, J.G.J.V. Aerts², G.M. Ribbers^{1,3}, H.J.G. van den Berg-Emons^{1**}, M.E. Hellemons^{2**} on
6 behalf of the CO-FLOW collaboration Group***

7 * Authors share first authorship. ** Share senior authorship

8 *** Collaboration Group authors mentioned on last page

9

10 **Affiliations:**

11 ¹Department of Rehabilitation Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.

12 ²Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.

13 ³Rijnndam Rehabilitation, Rotterdam, The Netherlands.

14 ⁴Department of Intensive Care, Erasmus Medical Center, Rotterdam, The Netherlands.

15

16

17 **Short title:** Persisting symptoms 12 months after COVID-19

18 **Correspondence:** M.E. Hellemons, Department of Respiratory Medicine, Erasmus Medical Centre, Dr.

19 Molewaterplein 40, 3015 GD Rotterdam, The Netherlands, m.hellemons@erasmusmc.nl

20

21 **ABSTRACT**

22 **Introduction:** A large proportion of patients experiences a wide range of sequelae after acute COVID-
23 19 infection, especially after severe illness. The long-term health sequelae need to be assessed. Our
24 objective was to longitudinally assess persistence of symptoms and clusters of symptoms up to 12
25 months after hospitalization for COVID-19, and to assess determinants of the main persistent
26 symptoms.

27 **Methods:** In this multicenter prospective cohort study patients with COVID-19 are followed up for 2
28 years with measurements at 3, 6, 12, and 24 months after hospital discharge. Here, we present
29 interim results regarding persistent symptoms up to 12 months. Symptoms were clustered into
30 physical, respiratory, cognitive and fatigue symptoms.

31 **Results:** We included 492 patients; mean age was 60.2±10.7 years, 335 (68.1%) males, median length
32 of hospital stay 11 (6.0-27.0) days. At 3 months after discharge 97.0% of the patients had at least 1
33 persisting symptom, this declined to 95.5% and 92.0% at 6 and 12 months, respectively ($p=0.010$).

34 Muscle weakness, exertional dyspnea, fatigue, and memory and concentration problems were the
35 most prevalent symptoms with rates over 50% during follow-up. Over time, muscle weakness, hair
36 loss, and exertional dyspnea decreased significantly ($p<0.001$), while other symptoms, such as
37 fatigue, concentration and memory problems, anosmia, and ageusia persisted. Symptoms from the
38 physical and respiratory cluster declined significantly over time, in contrast to symptoms from the
39 fatigue and cognitive clusters. Female gender was the most important predictor of persistent
40 symptoms and co-occurrence of symptoms from all clusters. Shorter hospital stay and treatment
41 with steroids were related with decreased muscle weakness; comorbidity and being employed were
42 related with increased fatigue; and shorter hospital stay and comorbidity were related with memory
43 problems.

44 **Conclusion:** The majority of patients experienced COVID-19 sequelae up to 12 months after
45 hospitalization. Whereas physical and respiratory symptoms showed slow gradual decline, fatigue
46 and cognitive symptoms did not evidently resolve over time. This finding stresses the importance of
47 finding the underlying causes and effective treatments for post-COVID condition, beside adequate
48 COVID-19 prevention.

49

50

51 **INTRODUCTION**

52 Acute coronavirus disease 2019 (COVID-19) infection in humans is associated with a heterogeneous
53 range of symptoms including respiratory, musculoskeletal, gastrointestinal, and neurological
54 symptoms. In 5-14% of patients the respiratory consequences of COVID-19 are severe, requiring
55 hospitalization for oxygen supplementation or even prolonged ventilatory support (1).

56 Whereas a proportion of patients fully recovers, it becomes increasingly clear that a proportion of
57 patients experiences a wide range of long-lasting sequelae after acute COVID-19 infection. Different
58 terms are currently used for describing the presence of post-COVID-19 symptoms, such as long
59 COVID, long haulers, post-COVID-19 syndrome, persistent post-COVID, and post-acute sequelae of
60 COVID (PASC). Although several definitions are in place, persistent symptoms after COVID-19 are
61 regarded as post-COVID-19 syndrome if they persist or present within 12 weeks of the onset of
62 acute COVID-19 and last for at least 2 months, and are not attributable to alternative diagnoses (2,
63 3). The more recent World Health Organization (WHO) definition of post COVID-19 condition (PCC) is
64 very similar to this definition, adding that symptoms may be new onset following initial recovery
65 from an acute COVID-19 episode or persist from the initial illness and must persist for at least two
66 months (4). Symptoms may also fluctuate or relapse over time. These post-acute COVID-19 sequelae
67 encompass a wide range of symptoms and organs systems. Common symptoms include fatigue,
68 shortness of breath and cognitive dysfunction (3, 4).

69 Although exact overall prevalence of these long-term symptoms remains unclear, it is estimated that
70 between 2.6% and 13.7% of symptomatic patients experience persistent symptoms beyond 12 weeks
71 after COVID-19 infection (5, 6). This number increases when patients are more severely affected (7).
72 A recent systematic review described that more than 50% of all patients (the majority after
73 hospitalization) experience post-acute COVID-19 sequelae, even up to 6 months after acute infection
74 (8). Recent data from a Chinese cohort demonstrated that symptoms were still present in over 68%
75 of hospitalized patients at 6 months after disease onset, decreasing to 49% at 12 months (9, 10).

76 The nature of the reported symptoms is diverse and ranges from exertional dyspnea to sensory
77 overload. Although studies have tried to phenotype the patients with residual symptoms, looked into
78 co-occurrence of pairs of post-COVID-19 symptoms, or report on assays of symptoms according to
79 various organ systems, it remains unclear how the various domains of symptoms relate to each other
80 and how frequently certain types of symptoms overlap (11-13).

81

82

83 Currently, most reports on persistent symptoms remain limited to 6 months after infection and little
84 is known regarding the determinants of persistent symptoms. Also, most studies are cross-sectional
85 and studies reporting outcomes across multiple time-points are scarce.

86 The aim of the current study was therefore to assess persistence of symptoms up to 12 months after
87 discharge, to evaluate how persistent symptoms and clusters of symptoms develop over time, to
88 determine how various clusters of symptoms overlap with each other, and to assess determinants of
89 the main persistent symptoms after COVID-19.

90

91

92

93

94

95 **METHODS**

96 Study design

97 The COvid-19 Follow-up care paths and Long-term Outcomes Within the Dutch health care system
98 (CO-FLOW) study is an ongoing multicenter prospective cohort study following COVID-19 patients
99 discharged from hospitals in the Rotterdam-Rijnmond-Delft region in the Netherlands. Detailed
100 description of its protocol can be found elsewhere (14). In short, up to 2 years after hospitalization
101 patients with COVID-19 are evaluated at 3, 6, 12, and 24 months after hospital discharge. Here, we
102 present interim results regarding persisting symptoms obtained in the period from July 1st 2020 until
103 December 1st 2021 as part of the CO-FLOW study up to 12 months after discharge. The Medical Ethics
104 Committee of the Erasmus Medical Center (MC) approved this study (MEC-2020-0487). The trial was
105 registered at The Netherlands Trial Register (NL8710), <https://www.trialregister.nl>, on June 12, 2020.

106 Adult patients (≥ 18 years of age) were eligible to participate in the CO-FLOW study if they had been
107 hospitalized for COVID-19 (diagnosis based on either positive reverse transcription polymerase chain
108 reaction or a clinical diagnosis combined with positive serology for COVID-19) within the previous 6
109 months and patient or relative had sufficient knowledge of the Dutch or English language.
110 Incapacitated patients were unable to participate given the study procedures. For this study only
111 participants with at least two study visits were included.

112

113 Study Procedures

114 Patients were recruited during outpatient follow-up after discharge in one of the participating
115 centers, at the inpatient rehabilitation center, or at the skilled nursing facility. All patients provided
116 written informed consent before the start of the measurements. Study visits were synchronized with
117 the patient's regular follow-up for COVID-19 at each of the participating centers if possible. When
118 patients were discharged from regular follow-up, study visits continued in the Erasmus University MC
119 or, if patients were unable to come to the Erasmus University MC, a research assistant performed the
120 study visit at home. During study visits patients performed non-invasive clinical tests, including
121 physical, psychological, and cognitive evaluation. At 3, 6, and 12 months follow-up visits, patients
122 received questionnaires via email or postal mail. Data were stored in Castor EDC (Castor EDC,
123 Amsterdam, The Netherlands).

124

125 Outcomes

126 A new Corona Symptom Checklist was developed for this study on 'novel or worsened symptoms
127 since the onset of COVID-19' during the first three months of the study, based on the first

128 experiences with post-COVID-19 patients. All questions are answered with “yes” or “no” (see
129 appendix for complete questionnaire). During the study visits the Corona Symptom Checklist was
130 administered by a research assistant in a face-to-face interview. As the Checklist was still under
131 development when the study started amid the beginning of the COVID-19 pandemic, it was
132 introduced at all study visits after August 5th 2020. As the pandemic evolved and knowledge
133 increased regarding PCC, additional questions were added (sensory overload, headache, chest pain)
134 from June 2021 onwards.

135 As fatigue is considered as one of the most prevalent symptoms in PCC, we chose to report fatigue
136 not based on the checklist results, but on the validated Fatigue Assessment Scale (FAS) that was
137 assessed in all patients since study onset. The FAS is a 10-item self-report questionnaire and is
138 validated in patients with chronic lung disease (15). The items are scored on a Likert scale ranging 1-
139 5. A total score of ≥ 22 is considered to represent substantial fatigue and was used to indicate
140 persisting fatigue (15).

141 Patient and clinical characteristics were collected at study visits and through electronic patient
142 records. Patients characteristics included age, sex, body mass index (BMI), migration background,
143 pre-COVID educational and employment status, smoking status, and comorbidities. Clinical
144 characteristics included baseline laboratory and radiological parameters, complications during
145 hospitalization including delirium and thrombosis, type and quantity of oxygen support, intensive
146 care unit (ICU) admission, length of stay (LOS) ICU, LOS hospital, and COVID-19 directed treatment
147 during hospital admission.

148

149 Statistical analyses

150 We examined descriptive statistics to ensure data met statistical assumptions. Variables were
151 presented as mean with standard deviation (SD), median with interquartile range, or numbers (n)
152 with percentages (%) as appropriate.

153 Patient reported symptoms were clustered into one of four clusters according to the nature of the
154 symptom: physical, respiratory, fatigue, and cognitive symptom cluster. The physical symptom
155 cluster was composed of the symptoms muscle weakness, balance problems/dizziness, joint pain,
156 tingling/numbness in extremities, hair loss, headache, chest pain, skin rash, vision problems,
157 hoarseness, anosmia, ageusia, stool problems, claudication, hearing problems, and miction problems.
158 The respiratory symptom cluster was composed of the symptoms exertional dyspnea, dyspnea,
159 cough, and phlegm. The fatigue symptom clusters was composed of fatigue and sleeping problems.
160 The cognitive symptom cluster was composed of the symptoms memory problems, concentration
161 problems, sensory overload, and anxiety/nightmares. If any of the symptoms in the clusters was

162 present at a time point, persisting symptoms in that cluster were scored as present at that time
163 point. We used generalized estimating equations (GEE) with an unstructured covariance matrix to
164 assess persistence of symptoms and symptom clusters over time. GEE accounts for correlations
165 between patient follow-up measurements and includes all observed outcomes despite incomplete
166 data. For longitudinal analyses, a Bonferroni correction was applied and a p-value <0.002 was
167 considered statistically significant. Difference in the distribution of symptom clusters across gender
168 were assessed with a Chi-Square test. Lastly, we performed multivariable logistic regression analyses
169 with a backward selection procedure to determine which variables are independently associated
170 with the most prevalent symptom per cluster at 3 months after discharge. The dependent variables
171 were muscle weakness, deconditioning/exertional dyspnea, fatigue, and memory problems. We only
172 reported determinants of symptoms at 3 months after discharge, as symptoms were most prevalent
173 at 3 months after discharge and the majority did not decrease significantly over time. Determinants
174 that were examined were age, sex, BMI, migration background (European, Dutch Caribbean, Asian,
175 Turkish, and (North) African), pre-COVID educational (low, middle, high) and employment status
176 (employed, not employed, retired), presence of comorbidity, smoking (never versus ever), BMI and
177 C-reactive protein (CRP) at admission, complications of thrombosis or delirium, oxygen
178 supplementation (none, nasal cannula or mask oxygen supplementation, high flow nasal cannula,
179 mechanical ventilation), LOS hospital, and COVID-19 directed treatment with steroids. The covariates
180 BMI and CRP were imputed with their mean value if missing. Variable elimination from the
181 multivariable models was based on goodness of fit using the likelihood ratio test with a p-value of
182 0.1, and the final models are presented with adjusted odds ratios (OR) and 95% confidence interval
183 (95%CI). All analyses were performed using Statistical Package for Social Sciences (SPSS) version 25
184 (IBM SPSS statistics, SPSS Inc, Chicago, IL, USA) and STATA version 8SE (StataCorp LLC, Texas, USA)
185 and R version 4.1.1 (R-Foundation) were used for graphs.

186

187

188 RESULTS

189 Characteristics

190 Between July 1st 2020 and December 1st 2021, a total of 650 patients were included in COFLOW, of
191 whom 492 participants underwent at least two study measurements and were included in this
192 interim analysis. Baseline characteristics are presented in table 1. Patients had a mean age of
193 60.2±10.7 years, 335 (68.1%) were male, 403 (81.9%) had one or more comorbidities: most
194 commonly obesity, cardiovascular, or pulmonary disease. Oxygen supplementation during admission
195 was required by 474 (96.3%) patients, 199 (40.4%) had been admitted to the ICU, with a median LOS
196 in ICU of 17 (9.0-30.5) days, and the median total LOS in the hospital was 11 (6.0-27.0) days. Of all
197 patients, 357 (72.6%) received any COVID-19 directed treatment, of whom 330 (70.8%) received any
198 form of steroids and 54 (11.5%) received directed anti-inflammatory treatment.

199 In total, 492 participant underwent at least two study measurements with the symptoms checklist.
200 The flowchart of the included patients and study measurements is shown in figure 1.

201

202 Persisting symptoms

203 Table 2 presents the number and proportion of patients with persisting symptoms at each follow-up
204 measurement. At 3 months after discharge, 97.0% of the patients had at least 1 persisting symptom,
205 this proportion of patients declined to 95.5% at 6 months and to 92.0% at 12 months ($p=0.010$).
206 Presence of a single symptom varied from 9.7% for miction problems to 81.8% for exertional
207 dyspnea. At all study visits, the most prevalent symptoms were muscle weakness, exertional
208 dyspnea, fatigue, and memory and concentration problems. These symptoms were reported by more
209 than 50% of the patients during follow-up; a large number of other persistent symptoms was
210 frequently reported, presented in table 2 and figure 2. Symptoms that significantly declined over
211 time were muscle weakness, hair loss, and exertional dyspnea ($p<0.001$).

212

213 Symptom clusters

214 The prevalence of symptoms and the overlap between symptom clusters at 3 months follow-up is
215 shown in figure 2. At 3 months, 90.7% of patients reported at least 1 symptom from the physical
216 symptom cluster; this declined significantly to 86.8% at 6 months and to 84.5% at 12 months
217 ($p=0.025$). Respiratory symptoms were reported by 87.3%, 79.1%, and 76.0% of the patients at 3, 6,
218 and 12 months, respectively ($p<0.001$). In the fatigue symptom cluster, 68.3% of the patients

219 reported a symptom at 3 months, 67.8% at 6 months, and 67.6% at 12 months ($p=0.082$). A symptom
220 from the cognitive symptom cluster was reported in 71.8% of the patients at 3 months, 70.0% at 6
221 months, and 74.2% at 12 months ($p=0.452$).

222 At 3 months after hospital discharge, 218 (56.3%) reported symptoms in all 4 symptoms clusters and
223 292 (75.5%) in 3 clusters. Symptoms in the physical and respiratory symptom clusters most
224 frequently overlapped (figure 3A). The majority of patients with fatigue also experience cognitive
225 symptoms (86.8%), and vice versa (83.4%). Isolated symptoms were rare, but concerned most
226 frequently fatigue in 21 (5.3%) patients or physical symptoms in 18 (4.6%) patients. Females more
227 frequently report symptoms in all four clusters than males (63% versus 52%, $p<0.001$) (figure 3B and
228 3C). Fatigue and cognitive symptoms were more frequent in female than in males (80.2% versus
229 68.6%, $p=0.002$), and 74.5% versus 68.6%, $p=0.009$, respectively), and so were the frequency of
230 respiratory (85.9% versus 85.5%, $p=0.022$) and physical symptoms (90% versus 88.5%, $p=0.002$).

231 In table 3 patient and clinical characteristics of patients hospitalized for COVID-19 at three months
232 follow-up are presented across the number of symptoms clusters affected. The majority of patients
233 (89%) experiences symptoms in 2 or more clusters. Several trends can be noticed in with increasing
234 number of symptoms clusters affected; more in females, patients with non-European background,
235 employment, co-morbidities and with lower CRP, lower D-dimer and more severely affected chest X-
236 ray upon admission. No association seems present with LOS, ICU admission and ventilation and with
237 COVID-19 directed treatment. As numbers per group/characteristic were limited, differences were
238 not statistically assessed and these trends should be considered as explorative and hypotheses
239 generating.

240

241 Determinants of persisting symptoms

242 Out of the physical symptom cluster, muscle weakness was the most frequently reported symptom
243 at 3 months after hospital discharge. Patients who were female (OR(95%CI):2.66 (1.62, 4.37),
244 $p<0.001$), had a longer LOS hospital (1.04 (1.02, 1.05), $p<0.001$) were more likely to experience
245 muscle weakness at 3 months after hospital discharge and patients who received steroids as
246 treatment during hospitalization (0.53 (0.29, 0.96), $p=0.036$) were less likely to experience muscle
247 weakness (figure 4). Out of the respiratory symptom cluster, exertional dyspnea was the most
248 prevalent symptom. We were unable to perform valid multivariable logistic regression on this
249 outcome given the high prevalence of this symptom (81.5%) at 3 months after hospital discharge.

250 Fatigue was the most prevalent symptom in the fatigue symptom cluster. Patients who were female
251 (2.76 (1.61, 4.76), $p<0.001$) and/or had comorbidities (2.19 (1.24, 3.87), $p=0.007$) were more likely to

252 develop fatigue symptoms, while patients who were retired (0.38 (0.22, 0.65), p=0.001) were less
253 likely to develop fatigue symptoms at 3 months after hospital discharge (figure 4).
254 At 3 months, memory problems was the most frequently reported symptom in the cognitive
255 symptom cluster. Patients who were female (2.01 (1.30, 3.39), p=0.002), had a shorter length of stay
256 (0.98 (0.97, 0.99), p=0.003), and/or had comorbidities (1.95 (1.12, 3.40), p=0.018) were more likely to
257 experience memory problems at 3 months after hospital discharge (figure 4).

258 **DISCUSSION**

259 Up to 12 months after hospitalization for COVID-19 over 90% of patients suffer from at least 1
260 persisting symptom. Muscle weakness, exertional dyspnea, fatigue, and memory and concentration
261 problems were the most prevalent symptoms with reporting rates over 50% of the patients at one of
262 the time points. Although several physical and respiratory symptoms (muscle weakness, hair loss,
263 exertional dyspnea) declined significantly over time, others - including fatigue and cognitive
264 symptoms - persisted.

265 Our findings support the observation from a recent meta-analysis describing that the short-term
266 prevalence of persisting symptoms were similar to long-term prevalence of symptoms, up to six
267 months after hospital discharge (8). Persisting symptoms are a common feature of COVID-19,
268 especially after hospitalization. To date, long-term data regarding persisting symptoms at 12 months
269 and beyond are limited. In a cohort study from Wuhan, the proportion of persistent symptoms was
270 shown to decrease from 68% at 6 months to 49% at 12 months after hospitalization (10). Although
271 this finding appears to contrast our findings, their cohort contained only 1% of patients that had
272 received mechanical ventilation compared to 35.6% in our cohort. The severity of the acute COVID-
273 19 infection is increasingly recognized to be associated with a larger proportion, and longer duration
274 of persisting symptoms and should thus be taken into account when comparing studies (16, 17). Our
275 study unfortunately shows a much less optimistic picture regarding recovery over time, with high
276 prevalence of persisting symptoms. More and longer term follow-up results will be collected to
277 obtain even more insight into the future outlook of these patients.

278 Looking into determinants, female gender was the most important predictor of persistent symptoms.
279 Earlier, we have demonstrated a relation of female gender with increased risk for fatigue up to six
280 months after discharge (7). Now we extend these findings to other symptoms and show that females
281 more frequently experience symptoms from multiple symptom clusters 3 months after
282 hospitalization. Previous studies have also demonstrated that female gender was associated with an
283 increased number of persisting symptoms (10, 18). It is frequently stated that, while acute cases of
284 COVID-19 tend to be most severe in older males, PCC seems to be more frequent in younger females.
285 Age however, was not found to be a determinant of persistent symptoms in our cohort, neither in
286 other studies after adjustment for confounders (10, 18). Also, it is necessary to bear in mind that
287 there may be a bias in symptoms reporting between males and females (19). We also found presence
288 of comorbidity to be associated with increased fatigue and memory problems, but this was not found
289 by others (10). It is well possible that pre-existent health problems make patients more vulnerable
290 for unfavorable outcome after severe illness.

291 Although numbers of acute COVID-19 may eventually decrease with increasing immunity in the
292 population, our findings point out that consequences will be long felt by many. As challenges in

293 vaccination programs worldwide continue to hinder effective control measures, the number of
294 people with PCC will only continue to increase. Vaccination may play an important role not only to
295 prevent new infections, but also in preventing PCC, as it was recently demonstrated that post-
296 vaccination breakthrough infections are less likely to be associated with symptoms persisting for
297 more than 28 days (20).

298 The best approach to PCC is unclear. As symptoms range from mild to severe and are very diverse in
299 nature, there is no one size fits all treatment possible. Although we grouped symptoms into clusters,
300 there are currently no universal recognized phenotypes, diagnostic criteria, minimal severity scores,
301 or a diagnostic test to establish a diagnosis of PCC. Establishing more objective and evidence-based
302 definitions and phenotypes of PCC will be necessary to compare findings across cohorts and settings,
303 and to establish evidence based interventions. Also, the impact of prior symptoms and prior
304 comorbidity need to be taken into account, just as the expected effects of hospitalization.

305 There are currently many unknowns regarding PCC, including the underlying mechanisms. Current
306 theories on PCC include virus-specific pathophysiologic changes, immunologic aberrations and
307 inflammatory damage in response to the acute infection, and expected sequelae of post-
308 critical illness (21). Indeed, it is very hard to differentiate between the expected sequelae, such as
309 described in the post-intensive care syndrome, and the sequelae that are specific for COVID-19 (22).
310 Nonetheless, in a large analysis on electronic health records data, key features of long-COVID (e.g.
311 breathlessness and fatigue) were more frequently reported after COVID-19 infection than in matched
312 controls after Influenza infection (13). Overall, it is becoming increasingly clear that the sequelae
313 after COVID-19 are more prevalent than after most other types of infections, persist for a long time,
314 and have a major impact on the burden of disease and health care.

315 Our study has several strengths and limitations. We followed a large cohort of patients in a
316 longitudinal design at 3, 6, and 12 months after hospital discharge. Currently, long-term follow-up
317 data are scarce. As the study is still ongoing, data were not complete for the entire cohort; also, the
318 initial patients were generally recruited between 3 and 6 months after hospital discharge, resulting in
319 unequal groups at different time points. We therefore included only participants with data of at least
320 two study measurements, and used GEE models to make maximal use of all data and to investigate
321 how symptoms developed over time.

322 One inclusion criterium was that patients or their relatives had to be able to communicate in Dutch
323 or English. Therefore, there is underrepresentation of individuals with a migration background in this
324 study compared to the community where this cohort was established. Nonetheless, 24% of the
325 participants in this cohort had a migration background; migration background was not a predictor of
326 residual symptoms in this study. Another limitation is that our results are only generalizable to

327 hospitalized patients. Also, we did not have patient scores on the severity of complaints. Even though
328 symptoms may persist for considerable time, the severity may very well decrease over time, as was
329 also shown in other studies (16).

330 To summarize, a large number of post COVID-19 patients experienced persistent symptoms up to 12
331 months after hospitalization for COVID-19. Whereas physical and respiratory symptoms show slow
332 gradual decline, fatigue and cognitive symptoms did not evidently resolve over time. This finding
333 stresses the importance of finding the underlying causes and effective treatments for PCC on the one
334 hand, and adequate COVID-19 prevention on the other hand. Large and long-term cohort studies
335 together with broader consortia are urgently needed to help better understand the trajectory,
336 complications, and biological mechanisms that drive persistent symptoms after COVID-19 infection.

337

338

339

340

341 **Table 1** Patient and clinical characteristics of patients hospitalized for COVID-19

	n	All (N=492)
Patient characteristic		
Age, years		60.2 ± 10.7
Sex, male		335 (68.1)
BMI, kg/m ²	437	29.3 ± 5.5
<i>Migration Background</i>	491	
European		373 (76.0)
Dutch Caribbean		61 (12.4)
Asian		25 (5.1)
Turkish		18 (3.7)
(North) African		14 (2.9)
<i>Pre-COVID education</i>	489	
Low		166 (33.9)
Middle		172 (35.2)
High		151 (30.9)
<i>Pre-COVID employment</i>	490	
Unemployed		77 (15.7)
Employed		297 (60.6)
Retired		116 (23.7)
<i>Smoking status</i>	491	
Never		211 (43.0)
Former		270 (55.0)
Current		10 (2.0)
<i>Comorbidities</i>		
≥1		403 (81.9)
Obesity (BMI≥30)		190 (38.6)
Diabetes		95 (19.3)
Cardiovascular disease/ hypertension		192 (39.0)
Pulmonary disease		119 (24.2)
Renal disease		46 (9.3)
Gastrointestinal disease		22 (4.5)
Neuromuscular disease		49 (10.0)
Malignancy		56 (11.4)
Autoimmune/inflammatory disease		54 (11.0)
Mental disorder		25 (5.1)
In-hospital characteristics		
PCR confirmed SARS-CoV-2		485 (98.6)
Serology confirmed SARS-CoV-2		7 (1.4)
<i>Laboratory values</i>		
Creatinine, umol/L	471	82.0 (69.0-100.0)
(CKD-EPI) eGFR, ml/min	456	82.0 (66.0-90.0)
CRP, mg/L	467	85.0 (47.0-154.0)

Ferritin, ug/L	284	832.5 (443.5-1613.3)
ALAT, U/L	457	37.0 (26.0-56.0)
Hemoglobin, mmol/L	468	8.6 (7.9-9.2)
MCV, fl	461	89.0 (85.0-91.0)
Trombocyten, 10 ⁹ /L	463	211.0 (159.0-276.0)
Lymphocytes absolute count, 10 ⁹ /L	325	0.9 (0.6-1.1)
D-dimer, mg/L	237	1.1 (0.6-380.0)
NT-pro-BNP, pmol/ml	90	18.5 (8.8-48.0)
IL-6, pmol/ml	36	55.5 (28.0-179.0)
<i>Chest x-ray abnormalities</i>	468	
Normal		59 (12.6)
Moderate		99 (21.2)
Severe		310 (66.2)
Thrombosis	484	79 (16.3)
Delirium	477	121 (25.4)
Requiring oxygen supplementation	492	474 (96.3)
Requiring high flow nasal cannula	462	150 (32.5)
ICU admission		199 (40.4)
Invasive mechanical ventilation		175 (35.6)
Length of intubation, days	167	14.0 (8.0-27.0)
Tracheostomy	482	64 (13.3)
Length of ICU stay, days	197	17.0 (9.0-30.5)
Length of hospital stay, days		11.0 (6.0-27.0)
<i>COVID-19 directed Treatment</i>	466	
None		109 (23.4)
(Hydroxy)chloroquine		14 (3.0)
Steroids		330 (70.8)
Antivirals		69 (14.8)
Anti-inflammatory (IL-6) treatment		54 (11.6)
Convalescent plasma		8 (1.7)
Monoclonal antibodies		0 (0.0)
Time interval between discharge and follow-up visit		
3 Months visit, days	385	94.7 ± 22.8
6 Months visit, days	483	184.8 ± 27.9
12 Months visit, days	271	368.3 ± 17.3

342

343 Data are presented as n (%), mean ± standard deviation, or, for non-normally distributed variables,
 344 median (interquartile range). □ Adjusted n is presented for variables with a total number of patients
 345 less than 492. BMI, Body Mass Index; IL-6, interleukin 6; PCR, Polymerase Chain Reaction, SARS-CoV-
 346 2, Severe Acute Respiratory Syndrome coronavirus 2; ICU, Intensive Care Unit.

347

348

349 **Table 2** Prevalence of COVID-19 related symptoms at 3, 6, and 12 months follow-up in patients after
 350 hospitalization for COVID-19

	3 Months (n=385) n (%)	6 Months (n=483) n (%)	12 Months (n=271) n (%)	p-value*
Physical symptoms				
Muscle weakness	220 (57.1)	234 (48.4)	111 (41.0)	<0.001
Balance problems/dizziness	169 (43.8)	213 (44.4)	116 (42.8)	0.922
Joint pain	166 (43.2)	201 (41.6)	111 (41.0)	0.352
Tingling/numbness in extremities	147 (36.8)	163 (33.9)	86 (32.1)	0.291
Hair loss	138 (35.9)	98 (20.3)	35 (12.9)	<0.001
Headache*	33 (31.4)	57 (26.1)	29 (18.6)	0.579
Chest pain*	29 (29.0)	40 (18.4)	28 (17.8)	0.069
Skin rash	99 (25.7)	132 (27.4)	82 (30.3)	0.587
Vision problems	97 (25.2)	148 (30.6)	78 (28.8)	0.023
Hoarseness	91 (23.6)	125 (25.9)	57 (21.0)	0.088
Anosmia	84 (21.9)	93 (19.3)	53 (19.6)	0.369
Ageusia	82 (21.2)	94 (19.5)	52 (19.2)	0.185
Stool problems	68 (17.7)	89 (18.5)	41 (15.1)	0.547
Claudication	54 (14.1)	68 (14.1)	27 (10.0)	0.116
Hearing problems	52 (13.5)	70 (14.5)	53 (19.6)	0.059
Miction problems	37 (9.7)	58 (12.1)	34 (12.5)	0.269
Respiratory symptoms				
Exertional dyspnea	315 (81.8)	345 (71.4)	171 (63.1)	<0.001
Dyspnea*	78 (66.1)	114 (51.8)	83 (52.9)	0.003
Cough	112 (29.0)	119 (24.7)	66 (24.4)	0.329
Phlegm	98 (25.5)	117 (24.2)	67 (24.7)	0.727
Fatigue symptoms				
Fatigue	243 (64.5)	277 (63.1)	156 (60.2)	0.932
Sleeping problems	141 (36.5)	172 (35.6)	96 (35.4)	0.777
Cognitive symptoms				
Memory problems	211 (54.7)	271 (56.1)	158 (58.3)	0.144
Concentration problems	206 (53.4)	249 (51.6)	140 (51.7)	0.826
Sensory overload*	44 (45.5)	93 (43.9)	58 (36.7)	0.503
Anxiety/nightmares	56 (14.5)	72 (14.9)	40 (14.8)	0.785

351 *Symptoms headache, chest pain, dyspnea, and sensory overload were added in a later stage,
 352 resulting in lower total numbers. Data are presented as n (%) indicating the number of patients with
 353 symptoms. p-values are based on Generalized Estimating Equation analyses, with follow-up visit as
 354 fixed factor and symptom (yes/no) at each follow-up visit as dependent variable. Bonferroni
 355 correction was applied for multiple testing, a p-value < 0.002 was considered statistically significant
 356 (printed in bold).

357

Table 3 Patient and clinical characteristics of patients hospitalized for COVID-19 divided by the number of symptoms clusters affected.

Patient characteristic	0 cluster (n=12)	1 cluster (n=28)	2 clusters (n=55)	3 clusters (n=74)	4 clusters (n=218)
Age, years	65.4 ± 11.8	63.0 ± 10.7	58.7 ± 11.6	61.7 ± 11.9	59.5 ± 9.8
Sex, male	12 (100.0)	23 (82.1)	44 (80.0)	54 (73.0)	141 (64.7)
BMI, kg/m ²	26.6 ± 4.0	27.7 ± 4.6	29.8 ± 5.4	29.1 ± 5.2	29.9 ± 5.8
<i>Migration Background</i>					
European	11 (91.7)	23 (82.1)	41 (74.5)	56 (75.7)	164 (75.2)
Dutch Caribbean	0 (0.0)	2 (7.1)	10 (18.2)	7 (9.5)	28 (12.8)
Asian	0 (0.0)	1 (3.6)	1 (1.8)	9 (12.2)	11 (5.0)
Turkish	0 (0.0)	0 (0.0)	3 (5.5)	2 (2.7)	8 (3.7)
(North) African	1 (8.3)	2 (7.1)	0 (0.0)	0 (0.0)	7 (3.2)
<i>Pre-COVID education</i>					
Low	4 (33.3)	8 (28.6)	18 (32.7)	29 (39.7)	73 (33.6)
Middle	5 (41.7)	11 (39.3)	18 (32.7)	21 (28.8)	81 (37.3)
High	3 (25.0)	9 (32.1)	19 (34.5)	23 (31.5)	63 (29.0)
<i>Pre-COVID employment</i>					
Unemployed	1 (8.3)	3 (10.7)	12 (21.8)	12 (16.4)	35 (16.1)
Employed	5 (41.7)	17 (60.7)	28 (50.9)	40 (54.8)	146 (67.0)
Retired	6 (50.0)	8 (28.6)	15 (27.3)	21 (28.8)	37 (17.0)
<i>Smoking status</i>					
Never	4 (33.3)	14 (50.0)	24 (43.6)	24 (32.4)	89 (40.8)
Former	8 (66.7)	14 (50.0)	30 (54.5)	50 (67.6)	123 (56.4)
Current	0 (0.0)	0 (0.0)	1 (1.8)	0 (0.0)	6 (2.8)
<i>Comorbidities</i>					
≥1	7 (58.3)	19 (67.9)	45 (81.8)	62 (83.8)	186 (85.3)
Obesity (BMI≥30)	2 (16.7)	7 (25.0)	22 (40.0)	31 (41.9)	84 (38.5)
Diabetes	2 (16.7)	6 (21.4)	12 (21.8)	12 (16.2)	46 (21.1)
Cardiovascular disease/ hypertension	3 (25.0)	10 (35.7)	17 (30.9)	35 (47.3)	88 (40.4)
Pulmonary disease	2 (16.7)	3 (10.7)	13 (23.6)	14 (18.9)	69 (31.7)
Renal disease	0 (100.0)	2 (7.1)	6 (10.9)	11 (14.9)	18 (8.3)
Gastrointestinal disease	0 (100.0)	0 (100.0)	3 (5.5)	3 (4.1)	7 (3.2)

Neuromuscular disease	1 (8.3)	3 (10.7)	5 (9.1)	7 (9.5)	19 (8.7)
Malignancy	1 (8.3)	4 (14.3)	4 (7.3)	16 (21.6)	22 (10.1)
Autoimmune/inflammatory disease	1 (8.3)	4 (14.3)	4 (7.3)	7 (9.5)	27 (12.4)
Mental disorder	0 (100.0)	3 (10.7)	2 (3.6)	3 (4.1)	13 (6.0)
In-hospital characteristics					
PCR confirmed SARS-CoV-2	12 (100.0)	28 (100.0)	55 (100.0)	73 (100.0)	215 (98.6)
Serology confirmed SARS-CoV-2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (1.8)
<i>Laboratory values</i>					
Creatinine, umol/L	75.0 (68.0-88.8)	83.0 (75.0-91.0)	86.0 (75.0-104.8)	84.0 (70.0-107.0)	82.0 (68.3-100.0)
(CKD-EPI) eGFR, ml/min	89.0 (76.3-90.0)	82.5 (71.3-90.0)	84.0 (59.5-90.0)	78.0 (61.0-90.0)	81.5 (66.0-90.0)
CRP, mg/L	143.0 (54.8-160.0)	112.0 (55.0-190.0)	109.0 (50.0-164.0)	81.5 (50.3-148.8)	85.0 (45.0-153.5)
Ferritin, ug/L	870.5 (686.8-1186.3)	1456.5 (411.3-2054.8)	1339.0 (515.3-1900.3)	980.0 (539.3-2410.5)	832.5 (435.5-1447.3)
ALAT, U/L	38.5 (21.8-43.8)	29.0 (20.0-56.0)	39.0 (29.5-53.0)	38.5 (24.8-62.3)	36.0 (26.0-58.0)
Hemoglobin, mmol/L	8.7 (8.3-9.2)	8.8 (8.0-9.8)	9.0 (7.9-9.3)	8.6 (7.7-9.2)	8.6 (8.0-9.2)
MCV, fl	90.0 (88.0-92.0)	88.0 (87.0-92.0)	88.0 (85.0-90.3)	88.0 (84.3-92.0)	88.0 (85.0-91.0)
Trombocytin, 10 ⁹ /L	289.0 (212.0-337.0)	199.5 (158.0-257.3)	218.0 (174.0-269.0)	191.0 (143.0-297.0)	216.0 (160.0-276.5)
Lymphocytes absolute count, 10 ⁹ /L	0.6 (0.5-1.0)	0.8 (0.6-1.2)	0.9 (0.6-1.1)	0.8 (0.5-1.0)	0.9 (0.6-1.1)
D-dimer, mg/L	929.0 (2.9-1522.0)	863.0 (420.0-2802.0)	1.2 (0.7-415.3)	1.0 (0.6-7.9)	1.2 (0.6-509.8)
NT-pro-BNP, pmol/ml	44.0 (18.0-na)	18.0 (5.0-na)	23.0 (7.5-42.0)	35.5 (19.3-77.3)	16.0 (7.0-42.0)
IL-6, pmol/ml	-	-	44.0 (32.0-83.8)	280.0 (52.5-614.5)	34.0 (26.0-191.0)
<i>Chest x-ray abnormalities</i>					
Normal	2 (16.7)	3 (10.7)	6 (11.3)	8 (11.4)	26 (12.7)
Moderate	4 (33.3)	6 (21.4)	10 (18.9)	17 (24.3)	45 (22.0)
Severe	6 (50.0)	19 (67.9)	37 (69.8)	45 (64.3)	134 (65.4)
Thrombosis	3 (25.0)	4 (14.3)	9 (16.4)	12 (16.7)	33 (15.4)
Delirium	1 (8.3)	5 (17.9)	19 (35.2)	22 (31.0)	45 (21.1)
Requiring oxygen supplementation	12 (100.0)	27 (96.4)	52 (94.5)	72 (97.3)	215 (98.6)
Requiring high flow nasal cannula	0 (0.0)	8 (28.6)	27 (50.9)	23 (32.4)	71 (34.1)
ICU admission	2 (16.7)	8 (28.6)	26 (47.3)	37 (50.0)	78 (35.8)
Invasive mechanical ventilation	2 (16.7)	6 (21.4)	22 (40.0)	35 (47.3)	69 (31.7)
Length of intubation, days	7.0 (3.0-na)	28.0 (11.0-30.0)	14.0 (8.5-23.5)	17.0 (7.0-32.0)	13.0 (7.8-23.0)
Tracheostomy	0 (0.0)	2 (7.4)	9 (16.4)	15 (21.1)	18 (8.3)
Length of ICU stay, days	10.0 (5.0-na)	17.0 (2.0-31.0)	16.0 (9.0-36.8)	22.0 (10.5-35.0)	14.0 (8.0-26.5)
Length of hospital stay, days	5.0 (2.3-8.5)	11.0 (4.3-22.0)	12.0 (6.0-31.0)	15.0 (7.0-39.0)	10.0 (5.0-23.0)

<i>COVID-19 directed Treatment</i>					
None	0 (0.0)	2 (8.0)	6 (11.5)	10 (14.7)	22 (10.3)
(Hydroxy)chloroquine	0 (0.0)	1 (4.0)	1 (1.9)	0 (0.0)	3 (1.4)
Steroids	11 (100.0)	21 (84.0)	44 (84.6)	57 (83.8)	181 (85.0)
Antivirals	1 (9.1)	3 (12.0)	10 (19.2)	12 (17.6)	35 (16.4)
Anti-inflammatory treatment	0 (0.0)	2 (8.0)	6 (11.5)	11 (16.2)	30 (14.1)
Convalescent plasma	0 (0.0)	0 (0.0)	3 (5.8)	1 (1.5)	2 (0.9)
Monoclonal antibodies	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Time interval between discharge and follow-up visit					
3 Months visit, days	91.4 ± 21.6	97.0 ± 12.2	95.3 ± 13.9	95.4 ± 21.5	94.2 ± 26.0
6 Months visit, days	186.8 ± 7.2	183.2 ± 10.3	191.4 ± 18.0	182.4 ± 47.0	184.4 ± 28.1
12 Months visit, days	358.3 ± 19.6	366.6 ± 10.6	365.7 ± 6.6	371.4 ± 22.8	369.3 ± 22.6

Data are presented as n (%), mean ± standard deviation, or, for non-normally distributed variables, median (interquartile range). Outcomes are stratified divided by the number of symptoms clusters affected (the four symptoms clusters comprise physical, respiratory, cognitive and fatigue symptoms).

▣ Adjusted n is presented for variables with a total number of patients less than 408. BMI, body mass index; PCR, Polymerase Chain Reaction, SARS-CoV-2, Severe Acute Respiratory Syndrome coronavirus 2; ICU, Intensive Care Unit; na, not applicable.

Figure 1: Flowchart of the patients in the CO-FLOW study during the interim analysis




Figure 2: Symptom prevalence over time




Figure legend: Prevalence of COVID-19-related symptoms at 3, 6, and 12 months follow-up in patients after hospitalization for COVID-19, sorted by symptoms cluster and from most to least frequently reported. Data are presented percentage of patients with symptoms. Symptoms marked with ◊ declined significantly over time based on Generalized Estimating Equation analyses, with follow-up visit as fixed factor and symptom (yes/no) at each follow-up visit as dependent variable.

Figure 3: Venn Diagrams showing overlap between the symptom clusters (physical symptoms, cognitive symptoms, fatigue symptoms and respiratory symptoms) for the entire cohort (A) and for males (B), and females (C).





Figure legend: Data are presented as n (%) indicating the number of patients with symptoms.

Figure 4. Forest Plot of the patient and admission characteristics associated with the most prevalent symptoms for the physical, fatigue and cognitive symptoms clusters obtained by multivariable logistic regression analyses



Appendix 1

Corona Symptom Checklist

The following complaints may be experienced after COVID-19 infection. Check for each question whether you experienced the complaint at this moment **and** is new since the COVID-19 infection. When you experienced the complaints already before the infection and this did not change, please check “no”. When the complaints *worsened* or is *new* after infection, please check “yes”.

Complaint:	Yes	No
Do you experience a reduced vision?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience a reduced hearing?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience a reduced taste?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience a reduced smell?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience coughing problems?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience phlegm?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience a reduced voice?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience balance problems or dizziness?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience stool problems?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience miction problems?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience fatigue?*	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience dyspnea?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience joint complaints?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience muscle weakness?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience reduced fitness?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience hair loss?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience skin rash?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience claudication?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience sensory overload?*	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience concentration problems?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience memory problems?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience headache?*	<input type="checkbox"/>	<input type="checkbox"/>

Do you experience sleeping problems?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience anxiety/nightmares?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience tingling and or pain in extremities?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience chest pain?*	<input type="checkbox"/>	<input type="checkbox"/>

*These questions were added from June 2021 onwards

References

1. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19). *JAMA*. 2020;324(8):782.
2. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. *BMJ*. 2020:m3026.
3. Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. *BMJ*. 2021:n136.
4. WHO. [Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1]
5. Sudre CH, Murray BA-OX, Varsavsky T, Graham MA-O, Penfold RS, Bowyer RA-O, et al. Attributes and predictors of long COVID. (1546-170X (Electronic)).
6. Ayoubkhani D. Statistical bulletin Office for National Statistics Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 Estimates of the prevalence of self-reported "long COVID", and the duration of ongoing symptoms following confirmed coronavirus infection, using UK Coronavirus (COVID-19) Infection Survey April 2021 [Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021>]
7. Hellemons ME, Huijts S, Bek L, Berentschot J, Nakshbandi G, Schurink CAM, et al. Persistent Health Problems beyond Pulmonary Recovery up to 6 Months after Hospitalization for SARS-CoV-2; A Longitudinal Study of Respiratory, Physical and Psychological Outcomes. *Annals of the American Thoracic Society*. 2021.
8. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. *JAMA Network Open*. 2021;4(10):e2128568-e.
9. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *The Lancet*. 2021;397(10270):220-32.
10. Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. *The Lancet*. 2021;398(10302):747-58.
11. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'Em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *EClinicalMedicine*. 2021;38:101019.
12. Estiri H, Strasser ZH, Brat GA, Semenov YR, Aaron JR, Agapito G, et al. Evolving phenotypes of non-hospitalized patients that indicate long COVID. *BMC Medicine*. 2021;19(1).
13. Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. *PLOS Medicine*. 2021;18(9):e1003773.
14. Bek LM, Berentschot JC, Hellemons ME, Huijts SM, Aerts J, van Bommel J, et al. CO-FLOW: COvid-19 Follow-up care paths and Long-term Outcomes Within the Dutch health care system: study protocol of a multicenter prospective cohort study following patients 2 years after hospital discharge. *BMC Health Serv Res*. 2021;21(1):847.
15. De Kleijn WPE, De Vries J, Wijnen PAHM, Drent M. Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis. *Respiratory Medicine*. 2011;105(9):1388-95.
16. Wynberg E, van Willigen H, Dijkstra M, Boyd A, Kootstra NA, van den Aardweg JG, et al. Evolution of COVID-19 symptoms during the first 9 months after illness onset. *medRxiv*. 2021:2021.05.05.21256710.
17. Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. Sequelae in Adults at 6 Months After COVID-19 Infection. *JAMA Network Open*. 2021;4(2):e210830.
18. Blomberg B, Mohn KG-I, Brokstad KA, Zhou F, Linchausen DW, Hansen B-A, et al. Long COVID in a prospective cohort of home-isolated patients. *Nature Medicine*. 2021;27(9):1607-13.

19. Bardel A, Wallander MA, Wallman T, Rosengren A, Johansson S, Eriksson H, et al. Age and sex related self-reported symptoms in a general population across 30 years: Patterns of reporting and secular trend. *PLoS One*. 2019;14(2):e0211532.
20. Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. *The Lancet Infectious Diseases*. 2021.
21. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, Mcgroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. *Nature Medicine*. 2021;27(4):601-15.
22. Kress JP, Hall JB. ICU-Acquired Weakness and Recovery from Critical Illness. *New England Journal of Medicine*. 2014;370(17):1626-35.

Acknowledgements

We would like to extend our gratitude to all the participants of the ongoing CO-FLOW study for their efforts, as well as all the entire group of measurement-assistants that currently assists in CO-FLOW: G.W.M. Broeren, R.M.B. Imkamp, J. Andela, L. Bierman, T. Huijboom, A. Luijckx, S. Roovers, I. Simons, and L. van Veggel

Funding

The study is funded by the COVID-19 Program Care and Prevention of The Netherlands Organization for Health Research and Development (ZonMw, grant number 10430022010026), and Rijndam Rehabilitation and Laurens (both in Rotterdam, The Netherlands). The review committee COVID-19 of the funding body has independently reviewed the study protocol. None of the funders have a role in the study design, nor are involved in analysis and interpretation of data or writing of the manuscript.

Author Contributions

LB, JB, MHK, HB, MH devised the main conceptual ideas and proof outline for this manuscript; LB, JB, MH included the patients; LB, JB contributed to data collection and aggregation; MH and JV designed the figures; LB, JB, MHK performed the statistical analyses; LB, JB, MHK, HB, MH wrote the manuscript. All authors were involved in the main study design, discussed the results, commented on the manuscript and approved the final manuscript.

Authors of the CO-FLOW collaboration Group

CO-FLOW collaboration Group

Michel E. van Genderen¹ Jasper van Bommel¹, Diederik A.M.P.J. Gommers¹, Erwin Ista^{2,3}, Robert van der Stoep⁴, Rutger Osterthun^{5,6}, Markus P.J.M. Wijffels⁶, Marieke M. Visser⁶, Janette J. Tazmi-Staal⁷, Eva G. Willems⁷, Roxane Heller⁸, Shai A. Gajadin⁹, Wouter J.B. Blox¹⁰, Laurien Oswald¹¹, Sieshem Bindraban¹¹, Rob Slingerland¹², Herbert J. van de Sande¹³, Ronald N. van Rossem¹⁴, Stephanie van Loon-Kooij¹⁴, L. Martine Bek⁵, Julia C. Berentschot¹⁵, Merel E. Hellemons¹⁵, Susanne M. Huijts¹⁵, Joachim G.J.V. Aerts¹⁵, Majanka H. Heijenbrok-Kal^{5,6}, Rita J.G. van den Berg-Emons⁵, Gerard M. Ribbers^{5,6}

ORCID IDs:

[0000-0001-5668-3435](https://orcid.org/0000-0001-5668-3435) Michel E. van Genderen

[0000-0001-8408-0500](https://orcid.org/0000-0001-8408-0500) Jasper van Bommel

[0000-0001-6808-7702](https://orcid.org/0000-0001-6808-7702) Diederik A.M.P.J. Gommers

[0000-0003-1257-3108](https://orcid.org/0000-0003-1257-3108) Erwin Ista

[0000-0001-9809-7311](https://orcid.org/0000-0001-9809-7311) Rutger Osterthun

[0000-0003-1472-7158](https://orcid.org/0000-0003-1472-7158) Eva G. Willems

[0000-0003-2706-0639](https://orcid.org/0000-0003-2706-0639) Laurien Oswald

[0000-0001-8257-7070](https://orcid.org/0000-0001-8257-7070) L. Martine Bek

[0000-0002-6666-5027](https://orcid.org/0000-0002-6666-5027) Merel E. Hellemons

[0000-0002-6652-6254](https://orcid.org/0000-0002-6652-6254) Susanne M. Huijts

[0000-0001-6662-2951](https://orcid.org/0000-0001-6662-2951) Joachim G.J.V. Aerts

[0000-0002-2982-4404](https://orcid.org/0000-0002-2982-4404) Majanka H. Heijenbrok-Kal

[0000-0001-6433-3398](https://orcid.org/0000-0001-6433-3398) Rita J.G. van den Berg-Emons

[0000-0002-6114-349X](https://orcid.org/0000-0002-6114-349X) Gerard M. Ribbers

Author details

¹Department of Adult Intensive Care Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands.

²Departments of Pediatrics and Pediatric Surgery, Intensive Care Unit, Erasmus MC Sophia Children's Hospital Rotterdam, The Netherlands.

³Department of Internal Medicine, section Nursing Science, Erasmus MC, Erasmus University Medical Center Rotterdam, The Netherlands.

⁴Department of Physical Therapy, Erasmus MC, University Medical Center Rotterdam, The Netherlands.

⁵Department of Rehabilitation Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands.

⁶Rijndam Rehabilitation, Rotterdam, The Netherlands.

⁷Laurens Intermezzo, Rotterdam, The Netherlands.

⁸Department of Respiratory Medicine, Ikazia Hospital, Rotterdam, The Netherlands.

⁹Department of Respiratory Medicine, IJsselland Hospital, Capelle aan de IJssel, The Netherlands.

¹⁰Department of Respiratory Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.


¹¹Department of Respiratory Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.




¹²Department of Respiratory Medicine, Maasstad Hospital, Rotterdam, The Netherlands.

¹³Aafje Nursing Home, Rotterdam, The Netherlands.


¹⁴Department of Respiratory Medicine, Reinier de Graaf Gasthuis, Delft, The Netherlands.

¹⁵Department of Respiratory Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands.






A. Overall Population



B. Males



C. Females

